secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001493152-24-012156
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate FY2023 net loss $23.5M; cash $52k; raised $10.7M in Q1 2024
---------------------------------------------------------------------

- Net loss widened to $23.5M in 2023 from $17.7M; R&D expense $15.5M (+72% YoY).
- Cash only $52k at year-end; $10.7M raised in Q1 2024 via ATM ($3.2M) and public offering ($7.5M).
- CTx-1301 Phase 3 adult data showed trend vs placebo but not statistically significant; effect size highlighted.
- FDA supports 505(b)(2) path for CTx-2103 (anxiety); IND design agreed.
- Jennifer Callahan promoted to CFO; three independent directors added in Feb 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315224012156/0001493152-24-012156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315224012156/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-012156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer